Posted by Michael Wonder on 02 Mar 2026
FDA accepts Viatris supplemental new drug application for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia
25 February 2026 - Viatris today announced that the US FDA has accepted for review the supplemental new drug application for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia.
The FDA has assigned a PDUFA goal date of 17 October 2026.
